HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.

AbstractBACKGROUND:
Alzheimer disease is a multifactorial disorder characterized by the progressive deterioration of neuronal networks. The pathological hallmarks includes extracellular amyloid plaques and intraneuronal neurofibrillary tangles, but the primary cause is only partially understood. Thus, there is growing interest in developing agents that might target multiple mechanisms leading to neuronal degeneration. CHF5074 is a nonsteroidal anti-inflammatory derivative that has been shown to behave as a γ-secretase modulator in vitro and to inhibit plaque deposition and to reverse memory deficit in vivo in transgenic mouse models of Alzheimer's disease (AD). In the present study, the effects of a long-term (13-month) treatment with CHF5074 on indicators of brain functionality and neurodegeneration in transgenic AD mice (Tg2576) have been assessed and compared with those induced by a prototypical γ-secretase inhibitor (DAPT).
RESULTS:
To this end, plaque-free, 6-month-old Tg2576 mice and wild-type littermates were fed with a diet containing CHF5074 (125 and 375 ppm/day), DAPT (375 ppm/day) or vehicle for 13 months. The measured indicators included object recognition memory, amyloid burden, brain oligomeric and plasma Aβ levels, intraneuronal Aβ, dendritic spine density/morphology, neuronal cyclin A positivity and activated microglia. Tg2576 mice fed with standard diet displayed an impairment of recognition memory. This deficit was completely reverted by the higher dose of CHF5074, while no effects were observed in DAPT-treated mice. Similarly, amyloid plaque burden, microglia activation and aberrant cell cycle events were significantly affected by CHF5074, but not DAPT, treatment. Both CHF5074 and DAPT reduced intraneuronal Aβ content, also increasing Aβ40 and Aβ42 plasma levels.
CONCLUSIONS:
This comparative analysis revealed a profoundly diverse range of clinically relevant effects differentiating the multifunctional anti-inflammatory derivative CHF5074 from the γ-secretase inhibitor DAPT and highlighted unique mechanisms and potential targets that may be crucial for neuroprotection in mouse models of AD.
AuthorsSandra Sivilia, Luca Lorenzini, Alessandro Giuliani, Marco Gusciglio, Mercedes Fernandez, Vito Antonio Baldassarro, Chiara Mangano, Luca Ferraro, Vladimiro Pietrini, Maria Francesca Baroc, Arturo R Viscomi, Simone Ottonello, Gino Villetti, Bruno P Imbimbo, Laura Calzà, Luciana Giardino
JournalBMC neuroscience (BMC Neurosci) Vol. 14 Pg. 44 (Apr 05 2013) ISSN: 1471-2202 [Electronic] England
PMID23560952 (Publication Type: Journal Article)
Chemical References
  • 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid
  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Antipsychotic Agents
  • Cyclin A
  • Cyclopropanes
  • Peptide Fragments
  • amyloid beta-protein (1-40)
  • amyloid beta-protein (1-42)
  • Flurbiprofen
  • Phosphopyruvate Hydratase
Topics
  • Alzheimer Disease (blood, drug therapy, genetics, pathology)
  • Amyloid beta-Peptides (blood, metabolism)
  • Amyloid beta-Protein Precursor (genetics)
  • Analysis of Variance
  • Animals
  • Antipsychotic Agents (therapeutic use)
  • Brain (pathology)
  • Cyclin A (metabolism)
  • Cyclopropanes (therapeutic use)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Exploratory Behavior (drug effects)
  • Female
  • Flurbiprofen (analogs & derivatives, therapeutic use)
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Microglia (pathology)
  • Mutation (genetics)
  • Peptide Fragments (blood)
  • Phosphopyruvate Hydratase (metabolism)
  • Plaque, Amyloid (pathology)
  • Recognition, Psychology (drug effects)
  • Silver Staining

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: